<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808167</url>
  </required_header>
  <id_info>
    <org_study_id>2018-2891</org_study_id>
    <nct_id>NCT04808167</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Conditioning in HSCT</brief_title>
  <acronym>RICH</acronym>
  <official_title>Remote Ischemic Conditioning for Protection From Treatment-related Cardiotoxicity in Pediatric and Adolescent Patients Undergoing Hematopoietic Stem Cell Transplantation: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center.&#xD;
      The hypothesis will be tested using a prospective study design. The purpose of the study is&#xD;
      to determine tolerability and safety of remote ischemic conditioning in pediatric and&#xD;
      adolescent patients undergoing HSCT, with the goal of a larger trial of efficacy to follow.&#xD;
      The secondary purpose is to determine if remote ischemic conditioning will reduce subclinical&#xD;
      cardiotoxicity as measured by markers of myocardial injury and stress in patients undergoing&#xD;
      HSCT. The study will include multiple blood collections and echocardiograms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2018</start_date>
  <completion_date type="Anticipated">August 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>18-24 months from start of enrollment</time_frame>
    <description>Patients undergoing HSCT will tolerate remote ischemic conditioning and there will be no adverse effect on therapeutic efficacy or co-morbidities.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hematopoietic Stem Cell Transplantations</condition>
  <arm_group>
    <arm_group_label>Therapeutic Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic group receives remote ischemic conditioning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group does not receive remote ischemic conditioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>autoRICÂ®</intervention_name>
    <description>The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.</description>
    <arm_group_label>Therapeutic Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pediatric, adolescent, or young adult patients, 10 years of age or above.&#xD;
&#xD;
          2. Able to tolerate upper arm blood pressure inflation.&#xD;
&#xD;
          3. Participating in the BMT Biorepository (2012-1156).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systolic blood pressure &gt;160 mmHg.&#xD;
&#xD;
          2. Previous diagnosis of cardiomyopathy (dilated, hypertrophic, restrictive, myocarditis)&#xD;
             or congenital heart disease other than bicuspid aortic valve.&#xD;
&#xD;
          3. Chronic kidney disease as defined as a pre-transplant GFR &lt;80&#xD;
&#xD;
          4. Central line in both upper extremities.&#xD;
&#xD;
          5. Known peripheral vascular disease or vasculitis.&#xD;
&#xD;
          6. Platelet count less than 30,000.&#xD;
&#xD;
          7. Known clotting disorder or hypercoagulability&#xD;
&#xD;
          8. Non-English speaking patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ryan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Banks</last_name>
    <phone>513-636-2147</phone>
    <email>mary.banks@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ryan</last_name>
      <phone>513-636-9282</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

